[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志 2018, 21(2):177-186.
[2] Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis, 2019, 39 (1): 86-95.
[3] Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol, 2017, 15 (10): 1604-1611.
[4] Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology, 2014, 59(5): 1772-1778.
[5] Lee MJ, Kim EH, Bae SJ, et al. Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: A 10-year retrospective cohort study. Gut Liver, 2019,13(1): 67-76.
[6] Fan JG, Wei L, Zhuang H, et al. Guideline of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis, 2019, 20(4): 163-173.
[7] Wang FS, Fan JG, Zhang Z,et al. The global burden of liver disease: the major impact of China. Hepatology, 2014,60(6): 2099-2108.
[8] Yu R, Shi QW, Liu L, et al. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: A Meta-analysis. BMC Gastroenterol, 2018, 18(1): 51.
[9] Kumar A, Davuluri G, Silva RN, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology, 2017, 65(6): 2045-2058.
[10] Di Palo DM, Garruti G, Di Ciaula A, et al. Increased colonic permeability and lifestyles as contributing factors to obesity and liver steatosis. Nutrients, 2020, 12(2):564.
[11] Pugin B, Barcik W, Westermann P, et al. A wide diversity of bacteria from the human gut produces and degrades biogenic amines. Microb Ecol Health Dis,2017, 28: 1353881.
[12] Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: A distinct entity shaped by differential metabolic adaptation. Hepatology, 2020,71(4):1213-1227.
[13] Shen F, Zheng RD, Sun XQ, et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int, 2017, 16(4): 375-381.
[14] Ni J, Shen TCD, Chen EZ, et al. A role for bacterial urease in gut dysbiosis and Crohn's disease. Sci Transl Med, 2017, 9 (416): eaah6888.
[15] Shen TC, Albenberg L, Bittinger K, et al. Engineering the gut microbiota to treat hyperammonemia. J Clin Invest, 2015, 125 (7): 2841-2850.
[16] De Chiara F, Heebøll S, Marrone G, et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol, 2018, 69(4): 905-915.
[17] Thomsen KL, Grønbæk H, Glavind E, et al. Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. Am J PhysiolGastrointest Liver Physiol, 2014, 307: G295–301.
[18] Heinritz SN, Weiss E, Eklund M, et al. Intestinal microbiota and microbial metabolites are changed in a pig model fed a high-fat/low-fiber or a low-fat/high-fiber diet. PLoS One, 2016,11(4): e0154329.
[19] Ticinesi A, Nouvenne A, Cerundolo N, et al. Gut microbiota, muscle mass and function in aging: A focus on physical frailty and sarcopenia. Nutrients, 2019, 11 (7): 1633.
[20] Lustgarten MS. The kidney-gut-muscle axis in end-stage renal disease is similarly represented in older adults. Nutrients, 2019, 12 (1):106.
[21] Walsh ME, Bhattacharya A, Sataranatarajan K, et al. The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging. Aging Cell, 2015, 14 (6): 957-970.
[22] Din USU, Brook MS, Selby A, et al. A double-blind placebo controlled trial into the impacts of HMB supplementation and exercise on free-living muscle protein synthesis, muscle mass and function, in older adults. Clin Nutr, 2019, 38 (5): 2071-2078.
[23] Dasarathy S, Mookerjee RP, Rackayova V, et al. Ammonia toxicity: from head to toe? Metab Brain Dis,2017,32: 529–538.
[24] Dasarathy S, Hatzoglou M. Hyperammonemia and proteostasis in cirrhosis. Curr Opin Clin Nutr Metab Care,2018,21(1): 30-36.
[25] Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol,2016, 65: 1232-1244.
[26] Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology, 2017, 65(6): 2045-2058.
[27] Guo Y, Wang H, Tang Y, et al. GCN2 deficiency protects mice from denervation-induced skeletal muscle atrophy via inhibiting FoxO3a nuclear translocation. Protein Cell, 2018, 9(11): 966-970.
[28] Cai X, Zhu C, Xu Y, et al Alpha-ketoglutarate promotes skeletal muscle hypertrophy and protein synthesis through Akt/mTOR signaling pathways. Sci Rep, 2016, 6: 26802.
[29] Cui T, Schally AV. Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1. Oncotarget,2018,9(47): 28745-28756.
[30] Zhai Y, Xiao Q, Miao J. The relationship between NAFLD and sarcopenia in elderly patients. Can J Gastroenterol Hepatol, 2018, 2018: 5016091.
[31] Kim G, Lee SE, Lee YB, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study. Hepatology, 2018, 68(5): 1755-1768.
[32] Son JW, Lee SS, Kim SR, et al. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. Diabetologia, 2017, 60(5): 865-872.
[33] Kim HY, Kim CW, Park CH, et al. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey. Hepatobiliary Pancreat Dis Int, 2016, 15(1): 39-47.
[34] Kim G, Lee SE, Jun JE, et al. Increase in relative skeletal muscle mass over time and its inverse association with metabolic syndrome development: a 7-year retrospective cohort study. Cardiovasc Diabetol, 2018, 17(1): 23.
[35] Zhang Y, Li R, Meng Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes, 2014, 63(2): 514-525.
[36] Machado MV, Yang Y, Diehl AM. The benefits of restraint: a pivotal role for IL-13 in hepatic glucose homeostasis. J Clin Invest, 2013, 123(1): 115-117.
[37] Duan Y, Li F, Wang W, et al. Interleukin-15 in obesity and metabolic dysfunction: current understanding and future perspectives. Obes Rev, 2017, 18(10): 1147-1158.
[38] Jindal A, Jagdish RK. Sarcopenia: Ammonia metabolism and hepatic encephalopathy. Clin Mol Hepatol, 2019, 25(3): 270-279.
[39] Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology, 2017, 65(6): 2045-2058.
[40] Butterworth RF. L-Ornithine L-aspartate for the treatment of sarcopenia in chronic liver disease: The taming of a vicious cycle. Can J Gastroenterol Hepatol, 2019, 2019: 8182195.
[41] Canbay A, Sowa JP. L-ornithine L-aspartate (LOLA) as a novel approach for therapy of non-alcoholic fatty liver disease. Drugs, 2019, 79(Suppl 1): 39-44.
[42] Hu YB, Chen Z, Fu RQ. The association between sarcopenia and non-alcoholic fatty liver disease. J Hepatol, 2017, 66(1): 243-244.
[43] Stern RA, Mozdziak PE. Glutamine synthetase in avian muscle contributes to a positive myogenic response to ammonia compared with mammalian muscle. Am J Physiol Regul Integr Comp Physiol, 2019, 317(1): R214-R221. |
